| Literature DB >> 28230287 |
Afsane Bahrami1,2, Majid Khazaei3, Malihe Hasanzadeh4, Soodabeh ShahidSales5, Mona Joudi Mashhad5, Marjaneh Farazestanian4, Hamid Reza Sadeghnia1, Majid Rezayi1, Mina Maftouh2, Seyed Mahdi Hassanian2,6, Amir Avan2,5.
Abstract
PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP-BEZ235, OSI-027, everolimus, MK-2206, KRX-0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer. J. Cell. Biochem. 119: 2460-2469, 2018.Entities:
Keywords: CELL SURVIVAL; COLORECTAL CANCER; PI3K/AKT/mTOR PATHWAY; THERAPEUTIC TARGET
Mesh：
Substances：
Year: 2017 PMID： 28230287 DOI： 10.1002/jcb.25950
Source DB: PubMed Journal: J Cell Biochem ISSN： 0730-2312 Impact factor: 4.429